Abstract
Endocrine therapy has developed rapidly and become most effective and clearly target form of adjuvant therapy for hormone sensitive breast cancer. Adjuvant endocrine therapy for breast cancer can be given after surgery or radiotherapy, and also prior, or subsequent to chemotherapy. Current commonly used drugs for adjuvant endocrine therapy can be divided into following three classes: selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs) and selective estrogen receptor down-regulators (SERDs). Unfortunately, tumor cells may develop resistance to endocrine therapy, which become a major obstacle limiting the success of breast cancer treatment. The complicated crosstalk, both genomic and nongenomic, between estrogen receptor and growth factors was considered to be a crucial factor contributing to endocrine resistance. However, the progression of resistance to endocrine therapy supposes to be a progressive, step-wise procedure and the underlying mechanism remains unclear. In this review, we would summarize the possible biology and molecular mechanisms that underlie endocrine resistance, and also some novel strategies to overcoming this issue.
Keywords: Endocrine therapy, Endocrine resistance, Estrogen receptor, HER2, AIs, SERMs, SERDs
Anti-Cancer Agents in Medicinal Chemistry
Title:Endocrine Therapy Resistance: Current Status, Possible Mechanisms and Overcoming Strategies
Volume: 13 Issue: 3
Author(s): Jinjia Chang and Weimin Fan
Affiliation:
Keywords: Endocrine therapy, Endocrine resistance, Estrogen receptor, HER2, AIs, SERMs, SERDs
Abstract: Endocrine therapy has developed rapidly and become most effective and clearly target form of adjuvant therapy for hormone sensitive breast cancer. Adjuvant endocrine therapy for breast cancer can be given after surgery or radiotherapy, and also prior, or subsequent to chemotherapy. Current commonly used drugs for adjuvant endocrine therapy can be divided into following three classes: selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs) and selective estrogen receptor down-regulators (SERDs). Unfortunately, tumor cells may develop resistance to endocrine therapy, which become a major obstacle limiting the success of breast cancer treatment. The complicated crosstalk, both genomic and nongenomic, between estrogen receptor and growth factors was considered to be a crucial factor contributing to endocrine resistance. However, the progression of resistance to endocrine therapy supposes to be a progressive, step-wise procedure and the underlying mechanism remains unclear. In this review, we would summarize the possible biology and molecular mechanisms that underlie endocrine resistance, and also some novel strategies to overcoming this issue.
Export Options
About this article
Cite this article as:
Chang Jinjia and Fan Weimin, Endocrine Therapy Resistance: Current Status, Possible Mechanisms and Overcoming Strategies, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (3) . https://dx.doi.org/10.2174/1871520611313030009
DOI https://dx.doi.org/10.2174/1871520611313030009 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Exploitation of Toll-like Receptor 3 Signaling in Cancer Therapy
Current Pharmaceutical Design SAR, QSAR and Docking of Anticancer Flavonoids and Variants: A Review
Current Topics in Medicinal Chemistry The Sphingolipid Rheostat: A Potential Target for Improving Pancreatic Islet Survival and Function
Endocrine, Metabolic & Immune Disorders - Drug Targets Repair and Translesion DNA Polymerases as Anticancer Drug Targets
Anti-Cancer Agents in Medicinal Chemistry Predictive Markers for Haematological Toxicity of Pemetrexed
Current Drug Targets Serum Carboxypeptidase N1 Serves as a Potential Biomarker Complementing CA15-3 for Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Criteria of Evidence to Move Potential Chemopreventive Agents into Late Phase Clinical Trials
Current Drug Targets Metalloproteinases and Metalloproteinase Inhibitors in Age-Related Diseases
Current Pharmaceutical Design Nutlins and Ionizing Radiation in Cancer Therapy
Current Pharmaceutical Design Advances in Drug Safety
Current Pharmaceutical Design Evaluation of Non-Coding RNAs as Potential Targets in Head and Neck Squamous Cell Carcinoma Cancer Stem Cells
Current Drug Targets Combating P-glycoprotein-Mediated Multidrug Resistance Using Therapeutic Nanoparticles
Current Pharmaceutical Design Economic and Cost-Effectiveness Considerations for Pharmacogenetics Tests: An Integral Part of Translational Research and Innovation Uptake in Personalized Medicine
Current Pharmacogenomics and Personalized Medicine The Novel Functions of cGMP-Specific Phosphodiesterase 5 and its Inhibitors in Carcinoma Cells and Pulmonary/Cardiovascular Vessels
Current Topics in Medicinal Chemistry Hedgehog Signaling and Urological Cancers
Current Drug Targets Impact of the Emulsification-Diffusion Method on the Development of Pharmaceutical Nanoparticles
Recent Patents on Drug Delivery & Formulation Recent Advances in pH-Sensitive Polymeric Nanoparticles for Smart Drug Delivery in Cancer Therapy
Current Drug Targets Synthesis and Apoptotic Activities of New 2(3H)-benzoxazolone Derivatives in Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry When Neighbors Talk: Colon Cancer Cell Invasion and Tumor Microenvironment Myofibroblasts
Current Drug Targets The Use of Immunotherapy to Treat Metastatic Breast Cancer
Current Medicinal Chemistry